Competitive bidding could get intense. There are a large number of big pharma companies with pipelines that are expiring and drying up. Combine that with very high market valuations and preferential tax treatment (both going forward and on repatriation) and you have a recipe for some serious cash on the barrelhead.
If Prurisol 2B turns out to be what we hope it is this is all amplified significantly.
Obviously Pfizer (Dr. B/ Harness), Novartis and Roche (p53 interest) are on the short list.
My guess is Celgene would not be in the running as they are probably the company that would like to see us, particularly Prurisol, fail.
There are probably a dozen others that could lock us down without blinking.
A health to IPIX!
(2)
(0)
Innovation Pharmaceuticals Inc (IPIX) Stock Research Links
All my posts are my own personal opinion and speculation. They should not be used as the basis for any investment decision. No, I am not Scottsmith.